close

Mergers and Acquisitions

Date: 2012-02-14

Type of information: Company acquisition

Acquired company: Nexus Oncology (UK)

Acquiring company: Ockham (USA)

Amount:

Terms:

 Ockham, a leading, global full-service contract research organization (CRO) with a focus in oncology, has completed the acquisition of Nexus Oncology. The transaction also provides Ockham with an institutional investment partner.
The combined company will operate under the Ockham name and will be led by Ockham's Chief Executive Officer, James V. Baker, and a joint Ockham and Nexus management team. Nexus Oncology will be known as Nexus Oncology, an Ockham Company.
Clare Wareing, founder of Nexus, will continue with the new organization serving as Chief Scientific Officer. In addition, the company's board of directors will have representatives from both the existing Ockham and Nexus boards.
With the addition of Nexus, Ockham now employs approximately 300 employees across 12 countries, placing it among top-tier niche CROs worldwide. This merger offers an enhanced global scale, a depth of oncology-specific therapeutic expertise, and new levels of operational excellence. The new organization is more strongly positioned to deliver oncologic clinical trials of all sizes across the drug development spectrum.
Nexus Oncology has over 120 staff across Europe, North America and Australasia. The company has experience in a wide variety of tumor types and is currently conducting Phase I-III oncology clinical trials across Europe, North America and Australasia.

Details:

Related:

CRO

Is general: Yes